KDE03401
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
CAS: 332348-12-6
A randomized, double-blind, placebo-controlled trial of abatacept for the treatment of relapsing, non-severe, granulomatosis with polyangiitis., PMID:40506793
Abatacept and multiple therapeutic bronchoscopies as salvage therapy for refractory tracheobronchial inflammation and stenosis in GPA., PMID:40506105
Optimal GVHD Prophylaxis., PMID:40488825
Allogeneic Transplantation for Older Adults., PMID:40488822
Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial., PMID:40480650
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders., PMID:40465294
Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future., PMID:40463417
Autoantibodies as prognostic markers in rheumatoid arthritis., PMID:40458132
Switching to IL-6 inhibitors or abatacept in elderly patients with rheumatoid arthritis achieving low disease activity with jak inhibitors: a pilot study., PMID:40455033
Multi-omics analysis of Helicobacter pylori-associated gastric cancer identifies hub genes as a novel therapeutic biomarker., PMID:40445003
FDA Approval Summary: Abatacept for prophylaxis of acute graft versus host disease., PMID:40435096
Interplay of Belatacept Immunosuppression and Maribavir Antiviral Activity in Recurrent CMV Viremia: Clinical Implications and Literature Review., PMID:40431608
New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review., PMID:40430462
β-Cell Function Derived From Routine Clinical Measures Reports and Predicts Treatment Response to Immunotherapy in Recent-Onset Type 1 Diabetes., PMID:40424079
Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A report from the CIBMTR., PMID:40398621
Disseminated cat-scratch disease during abatacept therapy for rheumatoid arthritis in an older patient: A case report and review of the literature., PMID:40379021
Humoral immunogenicity after vaccination with the fourth dose of COVID-19 in patients with immunomediated inflammatory diseases., PMID:40378626
Belatacept Conversion in Kidney Transplant Recipients with Congestive Heart Failure: Survival and 30-Day Readmission Outcomes., PMID:40374481
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis., PMID:40347194
The Role of Abatacept on Inflammation and Fibrosis in Hypochlorous Acid-Induced Fibrosis Mice., PMID:40344312
Abatacept-induced lupus erythematosus tumidus: A case report and literature review., PMID:40342196
Cost evaluation in head and neck cancer clinical trials: implications for high-value care., PMID:40339439
Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis., PMID:40335724
Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland., PMID:40334913
Abatacept for acute graft versus host disease prophylaxis in children with sickle cell disease patients undergoing HLA identical sibling hematopoietic stem cell transplantation., PMID:40301664
SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial., PMID:40297751
Toxoplasma Gondii Replication During Belatacept Treatment in Kidney Transplantation: A Case Report and a Review of the Literature., PMID:40282351
Post-transplant cyclophosphamide, abatacept, and vedolizumab to prevent GVHD after hematopoietic stem cells transplantation in children with acute leukemia: results of a prospective trial., PMID:40281208
Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: A propensity score-matched, active-comparator, new-user study., PMID:40280051
Short Form-36 psychometric properties in idiopathic inflammatory myopathies: reliability, validity, and responsiveness., PMID:40279268
Real-World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020-2022., PMID:40276902
Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD)., PMID:40272902
Macrophage-Tased Dual-Phase T Cell Immunomodulation to Combat Transplant Rejection., PMID:40264278
Transitional and CD21- PD-1+ B cells are associated with remission in early rheumatoid arthritis., PMID:40259340
Recommendations for the use of DMARDs in pregnancy and reproductive health for patients with rheumatic disease: A scoping review., PMID:40256995
Characterising infusion/injection-related reactions in patients with rheumatoid arthritis treated with biologic agents., PMID:40249052
Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction., PMID:40246381
Macrophage requirements for abatacept response in rheumatoid arthritis., PMID:40242906
Long-Term Outcomes of Belatacept Versus Tacrolimus Following T-Cell Depleting Induction in Adult Kidney Transplantation., PMID:40232892
Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis - a retrospective analysis from the RHADAR database., PMID:40232336
Impact of csDMARDs vs. b/tsDMARDs on the Prognosis of Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multicenter, Retrospective Study., PMID:40218150
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors., PMID:40199607
Emerging therapeutics in the management of food allergy., PMID:40189990
Updates in Diagnosis and Treatment of Immune Checkpoint Inhibitor Myocarditis., PMID:40178703
Verification of unmet medical needs in patients with juvenile idiopathic arthritis in Japan., PMID:40160024
Successful treatment of rheumatoid arthritis complicated by anti-Jo-1 antibody-positive myopathy with abatacept: A case report., PMID:40159152
Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment., PMID:40142915
Update in GVHD Prophylaxis: Novel Pharmacologic and Graft Manipulation Strategies., PMID:40123545
Anti-Rheumatic potential of biological DMARDS and protagonistic role of bio-markers in early detection and management of rheumatoid arthritis., PMID:40091354
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
